Today Biogen Idec BIIB +9.48% announced positive top-line results from CONFIRM, the second of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 (dimethyl ...
WESTON, Mass.--(BUSINESS WIRE)-- Today Biogen Idec (NASDAQ: BIIB) announced positive top-line results from CONFIRM, the second of two pivotal Phase 3 clinical trials designed to evaluate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results